{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 83,
  "pageCount": 366,
  "prevPage": 82,
  "nextPage": 84,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a Q&A format to present expert testimony as evidence of product failure.",
  "elementsJson": [
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/83",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-83",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We took it to clinical, Phase 1 later on, six years, and it failed again.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccf-7c0c35cbeb22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.37
      },
      "kind": "list",
      "text": "Compounds were so poor that always failed in phase 1 PK studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7851462d-122b-4897-9e5f-2af64ef1ff37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "Variability is 300% from patient to patient, up to >10X; tried similar dose ranges as pitolisant studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abb08b8b-4281-4195-8b60-2dad516526f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "A: “...your main problem is around basically the active substance present in the blood and then passing the blood-brain barrier to allow efficacy because it degrades very quickly into metabolites, and the variability is almost 300% intersubject.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "457b2d85-d474-4b8e-a084-06ed9cca01c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "paragraph",
      "text": "A: “When we stopped, we stopped directly after the Phase I pharmacokinetic-pharmacodynamic studies. We didn’t go any further after that. We did a PK study in 2017-2018.” Q: “Was this published anywhere?” A: “No, it’s not published.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4cb58911-b8b8-4eed-b95f-1c145434c5ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "A: “That’s a predecessor. That’s why I told you it started in 2012. That’s a predecessor from the optimized compound. We took it to clinical, Phase 1 later on, six years, and it failed again.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5bbb0f54-f758-4aef-9045-50f50445dce7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "The studies are unpublished, but he shared the findings and some data: 1) lack of bioavailability in the blood as “it degrades very quickly into metabolites”; 2) failure to pass the blood-brain barrier; and 3) massive plasma variability of drug from patient to patient, which he indicated was >300% but provided data suggesting it can very by more than 10-fold, far past the toxicity threshold.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef97330d-ad32-441f-9f8e-117f3b64fdbb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"We took it to clinical, Phase 1 later on, six years, and it failed again.\" — Senior pharmaceutical executive/scientist, previously at Abbott and now at another major pharma company",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccf-81f39efc3110",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9f42b27-4e29-408c-9c9f-263a8c1278c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "The ex-Abbott scientist indicated he was personally involved with multiple attempts with various H3 compounds over many years, which generally failed in phase 1 pharmacokinetic studies and used similar doses to pitolisant.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e87cf50-e8f7-4943-906b-3bd7bff63a7d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}